[1]解洪涛,张 顺△,曾广伟.当归补血方联合西药治疗冠脉搭桥术后疗效及对患者血瘀证证候评分和凝血功能的影响*[J].陕西中医,2019,(10):1341-1344.
　XIE Hongtao,ZHANG Shun,ZENG Guangwei..Effects of Danggui Buxue prescription combined with western medicine on blood stasis and coagulation function after coronary artery bypass grafting[J].,2019,(10):1341-1344.
点击复制

当归补血方联合西药治疗冠脉搭桥术后疗效及对患者血瘀证证候评分和凝血功能的影响*
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2019年10期
页码:
1341-1344
栏目:
临床研究
出版日期:
2019-10-05

文章信息/Info

Title:
Effects of Danggui Buxue prescription combined with western medicine on blood stasis and coagulation function after coronary artery bypass grafting
文章编号:
DOI:10.3969/j.issn.10007369.2019.10.006
作者:
解洪涛1; 张 顺1△; 曾广伟2
1.陕西中医药大学第二附属医院（咸阳 712000）；2.空军军医大学唐都医院（西安 710038）
Author(s):
XIE Hongtao; ZHANG Shun; ZENG Guangwei.
The Second Affiliated Hospital of Shaanxi University of Chinese Medicine （Xianyang 712000）
关键词:
冠心病; 冠状动脉搭桥术; 当归补血方; 血瘀证; 凝血功能; 凝血酶原时间; 纤维蛋白原
Keywords:
Key words 〖HT5”SS〗Coronary heart disease; Coronary artery bypass surgery; Danggui Buxue prescription; Blood stasis syndrome; Blood coagulation function; Prothrombin time; Fibrinogen
分类号:
R541.4
文献标志码:
A
摘要:
摘 要 目的：研究当归补血方联合西药治疗冠脉搭桥术后疗效和对患者血瘀证及凝血功能的影响。方法：选取行冠状动脉搭桥术的210例患者为研究对象，以随机数表法分为观察组与对照组，每组105例。对照组术后给予常规西药治疗，观察组在对照组基础上给予当归补血方。对比两组临床疗效及治疗前后凝血功能\[凝血酶原时间（PT）、国际标准化比值（INR）、纤维蛋白原（FIB）、活化部分凝血活酶时间（APTT）\]、血瘀证（黑便、腹壁静脉曲张、细络、持续心绞痛、舌质紫暗、脉涩、皮肤粗糙、皮下淤血、腭黏膜征阳性、舌下静脉曲张、少腹抵抗压痛）评分，另外观察两组患者用药期间不良反应情况。结果：观察组治疗后临床疗效总有效率89.52%显著高于对照组79.05%，差异有统计学意义（P＜0.05）；观察组治疗后 PT、INR、APTT水平与治疗前及对照组治疗后对比显著提高，差异有统计学意义（P＜0.05），观察组治疗后FIB水平与治疗前及对照组治疗后对比显著降低，差异有统计学意义（P＜0.05）；观察组治疗后黑便、细络、舌质紫暗、脉涩、皮肤粗糙、皮下淤血、腭黏膜征阳性、少腹抵抗压痛评分与治疗前及对照组治疗后对比显著降低，差异有统计学意义（P＜0.05）；两组患者用药期间均未见明显不良反应，肝肾功能检查无异常。结论：冠心病患者行冠状动脉搭桥术后给予当归补血方联合西药治疗可有效改善患者心功能，相对于单纯西药治疗联合用药可更好的发挥抗凝作用，降低血瘀证证候评分，且用药安全，值得临床应用。
Abstract:
Abstract 〖HT5”SS〗Objective：To study the effect of Danggui Buxue prescription combined with western medicine on blood stasis and coagulation function after coronary artery bypass grafting.Methods：210 patients who underwent coronary artery bypass grafting were selected as study subjects. They were divided into observation group and control group by the random number table method，with 105 patients in each group.The control group was treated with conventional western medicine after surgery and the observation group was given Danggui Buxue prescription on the basis of the control group.Compared two groups of clinical curative effect and treatment before and after the PT and INR，FIB，APTT，black stool，varicose veins，abdominal wall thin collaterals，continuous angina，dark purple tongue，pulse dry，rough skin，subcutaneous ecchymosis，palatal mucosal） positive resistance，sublingual veins，lower abdomen tenderness the indicators of change，in addition to observe two groups of patients with drug adverse reaction during the study.Results:The total effective rate of the observation group after treatment was 89.52%，which was significantly higher than that of the control group （79.05%）（P＜0.05）.After treatment，the levels of PT，INR and APTT in the observation group were significantly higher than those before treatment and those in the control group（P＜0.05）.The level of FIB in the observation group after treatment was significantly lower than that before treatment and that in the control group （P＜0.05）.After treatment，black stool，thin collaterals，glossal purple dark，palsy astringency，rough skin，subcutaneous congestion，positive palatal mucosal sign，hypogastrismalgia score were significantly decreased in the observation group compared with that before treatment and after treatment in the control group，with〖LM〗 statistically significant differences （P＜0.05）.No obvious adverse reactions were observed during the administration of the two groups，and there was no abnormality in the examination of liver and kidney function.Conclusion：After coronary artery bypass surgery in patients with coronary heart disease，the combination of Danggui Buxue prescription and western medicine can effectively improve the cardiac function of patients. Compared with the combination of western medicine alone，it can better play the anticoagulant effect，reduce the syndrome score of blood stasis，and the medication is safe and worthy of clinical promotion.

参考文献/References:

[1] 王三合，王治伦. 曲美他嗪联合通心络胶囊治疗冠心病心绞痛疗效观察[J]. 陕西中医，2016，37（2）：169170.
[2] 刘晓霞. 阿托伐他汀对冠心病患者血脂指标及一氧化氮、高敏C反应蛋白、血管内皮功能的影响[J]. 海军医学杂志，2016，37（3）：262263.
[3] 陈 鹏. 辨证论治冠心病冠状动脉搭桥术围手术期患者30例[J]. 西部中医药，2017，30（10）：8385.
[4] 李伟玲. 阿司匹林联合替罗非班预防冠心病 PCI 术后血栓形成100例分析[J]. 陕西医学杂志，2017，46（1）：112114.
[5] 杜 蕊，陈 民，李文杰. 冠状动脉粥样硬化性心脏病中医病机研究进展[J]. 现代中西医结合杂志，2016，25（16）：18181821.
[6] 国家食品药品监督管理局. 中药新药临床研究指导原则（试行）[M]. 北京：中国医药科技出版社，2002：234235.
[7] 中国中西医结合学会活血化瘀专业委员会. 血瘀证中西医结合诊疗共识[J]. 中国中西医结合杂志，2011，31（6）：839844.
[8] 复旦大学上海医学院. 实用内科学[M]. 12版.北京：人民卫生出版社，2005：14721473.
[9] 汤世民，邢小燕，邓雪红，等. 冠心丹参方及其有效成分治疗冠心病的研究进展[J]. 中国中药杂志，2016，41（20）：37213726.
[10] 孙铭鸿，张 艳，肖 阳，等. 冠心病不同类型与中医病机辨证的关系[J]. 中西医结合心脑血管病杂志，2017，15（4）：507508.
[11] 崔 爽.当归补血汤联合卡维地洛治疗心肌缺血疗效观察[J].中药药理与临床，2017，33（2）：197199.
[12] 曲远青，刘 涛，刘 媛，等. 不同病程的细菌性炎症患者中降钙素原与凝血功能指标的相关性分析[J]. 免疫学杂志，2015，31（5）：417420.
[13] 刘根斌，陈端英，何孙本. 评价温度和时间对血凝四项PT、FIB、APTT和TT结果的影响研究[J]. 现代预防医学，2016，43（5）：887890.
[14] 田新玮，刘丽丹，游碧荣，等. 活血化瘀方联合来氟米特及甲氨蝶呤对类风湿关节炎患者凝血功能的影响[J]. 陕西中医，2018，39（10）：117119.
[15] 刘露丝，彭 成，熊 亮. 当归苯酞类化合物的研究进展[J]. 世界科学技术中医药现代化，2015，17（5）：958962.
[16] 耿诗涵，许梦习，刘晓光，等. 注射用丹参多酚酸与阿司匹林联合应用对抗凝效果和出血风险的影响[J]. 中国药学杂志，2018，53（1）：3539.
[17] 叶世静，姚 权，张 军，等. 当归补血汤加味在全膝关节置换术后贫血20例中的应用[J]. 中国民族民间医药，2015，24（14）：39.

相似文献/References:

[1]朱 薇.通脉调脂方治疗冠心病稳定性心绞痛疗效及对患者血流变、VCAM1〖JZ〗及ICAM1影响的研究*[J].陕西中医,2019,(3):290.
　ZHU Wei..Effect of Tongmai Tiaozhi recipe on the efficacy, Hemorheology, VCAM1 and ICAM1 〖JZ〗in patients with stable angina pectoris of coronary heart disease[J].,2019,(10):290.
[2]时晓华.丹参多酚酸盐注射液辅助介入治疗冠心病 及对患者心、肾功能和心肌损伤的影响*[J].陕西中医,2019,(5):568.
　SHI Xiaohua..Effects of salvianolate injection on cardiac function, renal function, myocardial injury in percutaneous coronary intervention postoperative patients with coronary heart disease[J].,2019,(10):568.
[3]刘 红,张玲燕,杨 玲.血府逐瘀汤治疗冠心病介入术后心绞痛临床研究[J].陕西中医,2019,(5):594.
　LIU Hong,ZHANG Lingyan,YANG Ling..Clinical observation of Xuefu Zhuyu decoction in the treatment of angina pectoris after PCI for coronary heart disease[J].,2019,(10):594.
[4]吕永飞,陈爱莲.益心康泰胶囊治疗冠心病经皮冠状动脉介入术术后疗效及对患者血流变、血管内皮功能的影响*[J].陕西中医,2019,(6):714.
　LV Yongfei,CHEN Ailian..Effect of Yixin Kangtai capsule on the curative effect hemorheology and vascular endothelial function after coronary artery disease PCI[J].,2019,(10):714.
[5]贺建涛,胡宇才,刘 磊.活血通络散治疗冠心病PCI术后心绞痛疗效研究*[J].陕西中医,2019,(7):854.
　HE Jiantao,HU Yucai,LIU Lei..Efficacy observation of Huoxue Tongluo powder in the treatment of angina pectoris after coronary heart disease PCI[J].,2019,(10):854.
[6]索晓菲,王亚红△,王居新,等.软坚通脉汤治疗冠心病PCI术后Ⅱ期心脏康复疗效〖JZ〗及对患者生活质量的影响*[J].陕西中医,2020,(1):29.
[7]尹 毅,李小兰△.益气活血汤联合尼可地尔治疗稳定性心绞痛疗效及对患者T淋巴细胞亚群的影响[J].陕西中医,2020,(7):888.[doi:DOI:10.3969/j.issn.10007369.2020.07.014]
[8]季学清,刘 萍△,陈宝瑾,等.冠心康方加减联合西药治疗冠心病合并2型糖尿病气虚痰瘀证疗效研究*[J].陕西中医,2020,(9):1208.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.008]
　JI Xueqing,LIU Ping,CHEN Baojin,et al.Efficacy of Guanxinkang preparation combined with western medicine in the treatment of coronary heart disease and type 2 diabetes mellitus with syndrome of Qixu Tanyu[J].,2020,(10):1208.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.008]
[9]董其浩,邓 兵.益脉强心汤对冠心病合并心衰患者心室重构及血清血小板活化因子、转化生长因子-β1的影响[J].陕西中医,2021,(7):883.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.018]
[10]龚显田,陈丽梅,李子才,等.瓜蒌薤白半夏汤合失笑散加减治疗冠心病心绞痛临床研究[J].陕西中医,2021,(7):886.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.019]
　GONG Xiantian,CHEN Limei,LI Zicai,et al.Clinical Study on Gualou Xiebai Banxia decoction and Shixiao powder modified in treating coronary heart disease angina pectoris[J].,2021,(10):886.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.019]

备注/Memo

备注/Memo:
*陕西省重点研发计划项目（2018SF085）
更新日期/Last Update: 2019-10-23